DPT-Hib vaccine
(Redirected from DTP-HbOC)
| Combination of | |
|---|---|
| Diphtheria vaccine | Vaccine |
| Tetanus vaccine | Vaccine |
| Pertussis vaccine | Vaccine |
| Hib vaccine | Vaccine |
| Clinical data | |
| Trade names | Tetramune |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | Intramuscular injection |
| ATC code | |
DPT-Hib vaccine is a combination vaccine whose generic name is diphtheria and tetanus toxoids and whole-cell pertussis vaccine adsorbed with Hib conjugate vaccine, sometimes abbreviated to DPT-Hib.[1] It protects against the infectious diseases diphtheria, tetanus, pertussis, and Haemophilus influenzae type B.[1]
A branded formulation was marketed in the US as Tetramune by Lederle Praxis Biologicals (subsequently acquired by Wyeth).[2] Tetramune has since been discontinued.[3][4]
References
[edit]- ^ a b "Diphtheria and Tetanus Toxoids and Pertussis Vaccine Adsorbed and Haemophilus B Conjugate Vaccine (Systemic)". Drugs.com. Archived from the original on 15 July 2018. Retrieved 15 July 2018.
- ^ Centers for Disease Control Prevention (CDC) (April 1993). "FDA approval of use of a new Haemophilus b conjugate vaccine and a combined diphtheria-tetanus-pertussis and Haemophilus b conjugate vaccine for infants and children". MMWR. Morbidity and Mortality Weekly Report. 42 (15). Centers for Disease Control and Prevention: 296–8. PMID 8479415. Retrieved 15 July 2018.
- ^ "Selected Discontinued U.S. Vaccines" (PDF). Centers for Disease Control and Prevention. Retrieved 15 July 2018.
- ^ Zarei AE, Almehdar HA, Redwan EM (2016). "Hib Vaccines: Past, Present, and Future Perspectives". Journal of Immunology Research. 2016: 7203587. doi:10.1155/2016/7203587. PMC 4745871. PMID 26904695.
Table 1
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |